$OTLC
Oncotelic Therapeutics, Inc.

2014 Q4 Form 10-Q Financial Statement

#000119312514410532 Filed on November 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $0.00 $0.00 $95.00K
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.040M $1.210M $1.580M
YoY Change 6.12% -23.42% 29.51%
% of Gross Profit
Research & Development $1.610M $2.240M $1.165M
YoY Change 43.75% 92.27% 14.78%
% of Gross Profit
Depreciation & Amortization $30.00K $20.00K $20.00K
YoY Change 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $2.650M $3.453M $2.742M
YoY Change 26.19% 25.93% 22.47%
Operating Profit -$3.453M -$2.647M
YoY Change 30.45% 18.22%
Interest Expense $0.00 $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $10.00K $1.000K $0.00
YoY Change -100.0%
Pretax Income -$2.640M -$3.450M -$2.650M
YoY Change 25.71% 30.19% 17.78%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.640M -$3.450M -$2.646M
YoY Change 25.71% 30.39% 17.76%
Net Earnings / Revenue -2785.26%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.13 -$0.17 -$1.88
COMMON SHARES
Basic Shares Outstanding 20.71M shares 20.71M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.03M $32.89M $8.780M
YoY Change 328.39% 274.6% 39.37%
Cash & Equivalents $30.03M $32.89M $8.780M
Short-Term Investments
Other Short-Term Assets $4.000K $1.000K $129.0K
YoY Change -94.03% -99.22% -60.91%
Inventory
Prepaid Expenses $318.0K $279.0K $172.0K
Receivables
Other Receivables
Total Short-Term Assets $30.35M $33.17M $9.098M
YoY Change 323.63% 264.55% 37.22%
LONG-TERM ASSETS
Property, Plant & Equipment $37.00K $30.00K $5.000K
YoY Change 2.78% 500.0% -75.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.00K $33.00K
YoY Change
Total Long-Term Assets $70.00K $86.00K $123.0K
YoY Change -45.74% -30.08% -48.75%
TOTAL ASSETS
Total Short-Term Assets $30.35M $33.17M $9.098M
Total Long-Term Assets $70.00K $86.00K $123.0K
Total Assets $30.42M $33.25M $9.221M
YoY Change 317.1% 260.62% 34.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $335.0K $365.0K $733.0K
YoY Change -29.62% -50.2% 43.73%
Accrued Expenses $1.080M $1.310M $780.0K
YoY Change 38.46% 67.95% 5.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.419M $1.674M $1.515M
YoY Change 13.43% 10.5% 21.2%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.419M $1.674M $1.515M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.420M $1.670M $1.520M
YoY Change 13.6% 9.87% 21.6%
SHAREHOLDERS EQUITY
Retained Earnings -$251.2M -$248.5M -$236.4M
YoY Change 5.3% 5.12%
Common Stock $280.2M $280.1M $244.1M
YoY Change 14.56% 14.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.00M $31.58M $7.706M
YoY Change
Total Liabilities & Shareholders Equity $30.42M $33.25M $9.221M
YoY Change 317.1% 260.62% 34.22%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$2.640M -$3.450M -$2.646M
YoY Change 25.71% 30.39% 17.76%
Depreciation, Depletion And Amortization $30.00K $20.00K $20.00K
YoY Change 0.0% 0.0% 0.0%
Cash From Operating Activities -$2.840M -$3.380M -$1.530M
YoY Change 33.33% 120.92% -29.49%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $10.00K
YoY Change -75.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$10.00K
YoY Change -75.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 2.570M
YoY Change -100.0% -100.0% 63.69%
NET CHANGE
Cash From Operating Activities -2.840M -3.380M -1.530M
Cash From Investing Activities -10.00K -10.00K
Cash From Financing Activities 0.000 0.000 2.570M
Net Change In Cash -2.850M -3.390M 1.040M
YoY Change 61.02% -425.96% -273.33%
FREE CASH FLOW
Cash From Operating Activities -$2.840M -$3.380M -$1.530M
Capital Expenditures $10.00K $10.00K
Free Cash Flow -$2.850M -$3.390M
YoY Change 31.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.75
CY2014Q1 oxgn Threshold Limit Percentage On Warrants Owned
ThresholdLimitPercentageOnWarrantsOwned
0.0999 pure
CY2014Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.90
CY2014Q2 oxgn Threshold Limit Percentage On Warrants Owned
ThresholdLimitPercentageOnWarrantsOwned
0.0499 pure
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20705514 shares
CY2013Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1377412 shares
CY2013Q3 us-gaap Cash
Cash
8777000
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20706000 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20706000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
539000 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.72
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
229000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.60
CY2014Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.24
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1054625 shares
CY2014Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7445000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.81
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
642000 shares
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
33000
CY2014Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
238000
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
279889000
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1674000
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
207000
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
365000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-248517000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
221000
CY2014Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
282000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
31579000
CY2014Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
286000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
992000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
215000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33253000
CY2014Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1476000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
209000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
202000
CY2014Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
811000
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
546000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
CY2014Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
23000
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2014Q3 us-gaap Assets
Assets
33253000
CY2014Q3 us-gaap Cash
Cash
32887000
CY2014Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1000
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
33167000
CY2014Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
279000
CY2014Q3 oxgn Purchase Commitment Amount Due
PurchaseCommitmentAmountDue
2547000
CY2014Q3 oxgn Purchase Commitment Estimated And Accrued
PurchaseCommitmentEstimatedAndAccrued
151000
CY2014Q3 oxgn Accrued Research And Development
AccruedResearchAndDevelopment
212000
CY2014Q3 oxgn Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Related Party
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRelatedParty
147145 shares
CY2014Q3 oxgn Future Purchase Commitment
FuturePurchaseCommitment
866000
CY2014Q3 oxgn Purchase Commitment Non Cancelable Contracts Obligation
PurchaseCommitmentNonCancelableContractsObligation
215000
CY2014Q3 oxgn Operating Lease Future Minimum Payments Due After Fourth Full Fiscal Year
OperatingLeaseFutureMinimumPaymentsDueAfterFourthFullFiscalYear
112000
CY2012Q4 us-gaap Cash
Cash
4946000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5586000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5586000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.54
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5178000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
192000 shares
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
268000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1251000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
56000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
476000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238508000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
244495000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
6043000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
342000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7294000
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1406000
CY2013Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
116000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36000
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
93000
CY2013Q4 us-gaap Assets
Assets
7294000
CY2013Q4 us-gaap Cash
Cash
7005000
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
67000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
7165000
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
93000
CY2013Q4 oxgn Accrued Research And Development
AccruedResearchAndDevelopment
317000
CY2014Q1 oxgn Proceeds From Issuance Of Common Stock And Warrants In Offering Gross
ProceedsFromIssuanceOfCommonStockAndWarrantsInOfferingGross
12000000
CY2014Q1 oxgn Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
10860000
CY2014Q1 oxgn Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2014Q2 oxgn Proceeds From Issuance Of Common Stock And Warrants In Offering Gross
ProceedsFromIssuanceOfCommonStockAndWarrantsInOfferingGross
16000000
CY2014Q2 oxgn Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
14822000
CY2014Q2 oxgn Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y3M18D
CY2014Q2 oxgn Increase In Threshold Limit Percentage On Warrants Owned
IncreaseInThresholdLimitPercentageOnWarrantsOwned
0.0999 pure
CY2013Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5000000
CY2013Q2 oxgn Proceeds From Issuance Initial Public Offering Net
ProceedsFromIssuanceInitialPublicOfferingNet
4192000
CY2013Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5800000
CY2013Q3 oxgn Proceeds From Issuance Initial Public Offering Net
ProceedsFromIssuanceInitialPublicOfferingNet
4905000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4871000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2268000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.84
us-gaap Sales Revenue Net
SalesRevenueNet
95000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
24000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6183000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10979000
us-gaap Net Income Loss
NetIncomeLoss
-6180000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
us-gaap Operating Expenses
OperatingExpenses
6278000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
6334000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2514000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
73000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4799000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3831000
us-gaap Depreciation
Depreciation
8000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8702000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1936000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2198000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3764000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
614000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
432000
us-gaap Share Based Compensation
ShareBasedCompensation
638000
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
OXIGENE INC
dei Trading Symbol
TradingSymbol
OXGN
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9305000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
491000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y6M7D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0157 pure
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 6pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of unaudited condensed financial statements in conformity with U.S.&#xA0;generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15716000 shares
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
33.40
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M10D
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M4D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
41000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.73
dei Entity Central Index Key
EntityCentralIndexKey
0000908259
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.01 pure
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
153000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10005000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
2396000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10009000
us-gaap Net Income Loss
NetIncomeLoss
-10009000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
us-gaap Operating Expenses
OperatingExpenses
10005000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5798000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
70000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
25882000
us-gaap Depreciation
Depreciation
12000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
35193000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25681000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4207000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
423000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9512000
us-gaap Share Based Compensation
ShareBasedCompensation
352000
oxgn Number Of Drug Candidates
NumberOfDrugCandidates
2 Candidate
oxgn Classes Of Warrants Or Right Term Exercise Period
ClassesOfWarrantsOrRightTermExercisePeriod
P5Y
oxgn Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
1054625 shares
oxgn Classes Or Warrant Right Expiration Date
ClassesOrWarrantRightExpirationDate
2014-07-20
oxgn Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo
P8Y8M1D
oxgn Payments To Acquire Property Plant Equipment And Other Assets
PaymentsToAcquirePropertyPlantEquipmentAndOtherAssets
6000
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2640000 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.88
CY2013Q3 us-gaap Sales Revenue Net
SalesRevenueNet
95000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2647000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4964000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-2646000
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
2742000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1165000
CY2013Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2318000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1577000
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20705000 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3453000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3450000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-3450000
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
3453000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2240000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1213000

Files In Submission

Name View Source Status
0001193125-14-410532-index-headers.html Edgar Link pending
0001193125-14-410532-index.html Edgar Link pending
0001193125-14-410532.txt Edgar Link pending
0001193125-14-410532-xbrl.zip Edgar Link pending
d799265d10q.htm Edgar Link pending
d799265dex101.htm Edgar Link pending
d799265dex102.htm Edgar Link pending
d799265dex311.htm Edgar Link pending
d799265dex312.htm Edgar Link pending
d799265dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
oxgn-20140930.xml Edgar Link completed
oxgn-20140930.xsd Edgar Link pending
oxgn-20140930_cal.xml Edgar Link unprocessable
oxgn-20140930_def.xml Edgar Link unprocessable
oxgn-20140930_lab.xml Edgar Link unprocessable
oxgn-20140930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending